Glycoprotein News and Research

RSS

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

In a recent bioRxiv* preprint paper, US researchers mapped in detail how mutations to the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected antibody binding in convalescent human serum – and revealed that it is influenced by mutations at only a handful of dominant epitopes.

6 Jan 2021

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Today, the U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.

18 Dec 2020

Remdesivir inhibits SARS-CoV-2 replication by preventing RdRp-mediated RNA translocation

A new study describes the in vitro mechanism by which remdesivir kinetically inhibits the replication of the virus that causes COVID-19, SARS-CoV-2.

18 Dec 2020

Rapid point-of-care lateral flow assay to assess the neutralizing activity of plasma against SARS-CoV-2

A new paper describes the development and validation of a rapid test to measure the neutralizing activity of serum against COVID-19 using a drop of blood.

18 Dec 2020

SARS-CoV-2 spike deletion ΔH69/ΔV70 shows repeated emergence and spread

Since the COVID 19 pandemic, it has been established that the causative virus, SARS-CoV-2 gains entry to the target host cell via its spike glycoprotein.

17 Dec 2020

Why are some groups more vulnerable to COVID-19?

News-Medical speaks to Dr. Jaswinder Singh about his research surrounding why some groups are more susceptible to severe cases of COVID-19.

17 Dec 2020

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Researchers have reported that the autoimmune PTPN2 risk variant rs1893217 promotes the expression of the SARS-CoV-2 receptor, ACE2, and thus promotes cellular entry, which is mediated by SARS-CoV-2 spike S protein.

16 Dec 2020

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

The focus is increasingly moving towards vaccine roll-out as the world faces the real possibility of the second year of social and economic restrictions.

14 Dec 2020

SARS-CoV-2 spike protein mediates acute lung pathology in mice

A study shows that the viral spike protein is adequate by itself to induce macrophage activation in pulmonary tissue and induce acute inflammation.

10 Dec 2020

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

A recent study by US researchers, currently available on the medRxiv preprint server, evaluated several cell-based assays that are under validation for determining correlates of protection in individuals with symptomatic coronavirus disease (COVID-19) and vaccine studies – and demonstrated their high concordance with both live and pseudotyped virions.

9 Dec 2020

Mount Sinai study shows strong immune response, durability of universal influenza virus vaccine

A vaccine that induces immune responses to a wide spectrum of influenza virus strains and subtypes has produced strong and durable results in early-stage clinical trials in humans, Mount Sinai researchers have found.

7 Dec 2020

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

A new study describes an ELISA assay that combines the detection of IgM, IgA, and IgG antibodies against the SARS−CoV−2 trimeric spike glycoprotein.

7 Dec 2020

Can melatonin help prevent severe COVID-19?

A team of researchers at the University of Toronto in Canada has found that melatonin can be an adjuvant to augment the efficacy of anti-SARS-CoV-2 vaccines. They believe that the drug is a potential “silver bullet” to combat the COVID-19 pandemic.

3 Dec 2020

COVID-19 mutation mapping identifies escape mutations against therapeutic antibodies

A new study maps all known mutations in the SARS-CoV-2 virus, showing how each contributes to escape from individual antibodies.

3 Dec 2020

Novel “multitope” vaccine shows promise in the fight against COVID-19

Researchers have demonstrated the potential of a protein-peptide vaccine to protect against infection with SARS-CoV-2, the agent that causes COVID-19.

3 Dec 2020

Spanish-originated SARS-CoV-2 variant A222V shows rapid spread in Lazio, Italy

A startling new study reports the rapid rise to dominance of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain in Italy. This strain, termed the GV clade, is characterized by a single point mutation.

2 Dec 2020

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

In a recent research letter published on the bioRxiv preprint server, scientists from Japan discovered that the mutation of spike glycoprotein in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) derived from farmed minks can also be found in the group of individuals with coronavirus disease (COVID-19) and subsequently evade detection by our immune system.

30 Nov 2020

Steam inhalation therapy found to inactivate SARS-CoV-2 virions

Researchers have published a study on the efficacy of steam inhalations as another possible treatment to help mitigate SARS-CoV-2 infection.

30 Nov 2020

Study exposes human olfactory and brain cells as genuine viral targets of SARS-CoV-2

In a study published in the iScience journal, a research group from Switzerland shows that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptors and entry genes are expressed in the human olfactory neuroepithelial cells and brain by observing key molecular players implicated in the infectious process

29 Nov 2020

Glycoprotein News and Research

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Remdesivir inhibits SARS-CoV-2 replication by preventing RdRp-mediated RNA translocation

Rapid point-of-care lateral flow assay to assess the neutralizing activity of plasma against SARS-CoV-2

SARS-CoV-2 spike deletion ΔH69/ΔV70 shows repeated emergence and spread

Why are some groups more vulnerable to COVID-19?

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Emergence of resistant SARS-CoV-2 variant in immunocompromised patient following therapeutic antibody use

SARS-CoV-2 spike protein mediates acute lung pathology in mice

Different SARS-CoV-2 neutralization assays are reliable and concordant for antibody monitoring

Mount Sinai study shows strong immune response, durability of universal influenza virus vaccine

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

Can melatonin help prevent severe COVID-19?

COVID-19 mutation mapping identifies escape mutations against therapeutic antibodies

Novel “multitope” vaccine shows promise in the fight against COVID-19

Spanish-originated SARS-CoV-2 variant A222V shows rapid spread in Lazio, Italy

A mutant SARS-CoV-2 subspecies from minks may evade antibody detection

Steam inhalation therapy found to inactivate SARS-CoV-2 virions

Study exposes human olfactory and brain cells as genuine viral targets of SARS-CoV-2

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News